00:45:25 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-14 Bokslutskommuniké 2024
2024-11-14 Kvartalsrapport 2024-Q3
2024-08-16 Kvartalsrapport 2024-Q2
2024-05-30 Årsstämma 2024
2024-05-17 Kvartalsrapport 2024-Q1
2024-03-01 Ordinarie utdelning CSMED 0.00 DKK
2024-02-14 Bokslutskommuniké 2023
2023-12-15 Ordinarie utdelning CSMED 0.00 DKK
2023-07-18 Kvartalsrapport 2023-Q3
2023-05-17 Kvartalsrapport 2023-Q2
2023-04-14 Extra Bolagsstämma 2023
2023-02-17 Kvartalsrapport 2023-Q1
2023-02-14 Årsstämma 2023
2023-02-10 Ordinarie utdelning CSMED 0.00 DKK
2022-11-18 Bokslutskommuniké 2022
2022-08-13 Kvartalsrapport 2022-Q3
2022-05-20 Kvartalsrapport 2022-Q2
2022-02-18 Kvartalsrapport 2022-Q1
2021-12-10 Ordinarie utdelning CSMED 0.00 DKK
2021-12-09 Årsstämma 2022
2021-11-18 Bokslutskommuniké 2021

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriLäkemedel & Handel
CS Medica är ett danskt medicintekniskt bolag, dedikerat till läkemedelsforskning, utveckling, tillverkning och global kommersialisering. Bolaget blandar vetenskap och natur för att förbättra patienters liv med cannabinoidterapier för smärtlindring, och för att hantera autoimmuna och stressrelaterade symtom. Globalt erbjuder CS Medica CBD-behandlingar över disk (OTC), inklusive patenterade medicinska produkter, MHRA och MDR-registrerade artiklar, under varumärket CANNASEN® eller med egen märkning.
2021-10-04 13:19:42

CS MEDICA A/S ("CS MEDICA" or the "Company") announces today, October 4, that the Company's purchase agreement together with Kronan Droghandel Apotek AB ("Kronans Apotek") will now also include product sales of their Cannasen® CBD product line in 326 local pharmacies in Sweden.

CS MEDICA is a Danish medico cannabis company that envisions playing a central role in ensuring the best treatments within healthcare and wellness for patients, healthcare professionals, and consumers around the world. The Company fulfills this purpose by introducing and providing the most effective and innovative OTC cannabinoid products.

Following the Company's strategy of expanding its market shares, the Company aims to finalize distributor agreements outside of Denmark. Currently, the Company is in the process of entering markets across various nations in Europe. One of the ongoing order discussions regards the purchase and resale agreement with Kronans Apotek in Sweden. As of March 17, 2021, the Company has a purchase agreement with Kronans Apotek covering Cannasen® CBD Arthritis gel & Cannasen® CBD Psoriasis Gel.

Kronans Apotek is currently selling the products in their webshop. In accordance with the purchase agreement, the products are entering the shelf of the 326 local pharmacies of Kronans Apotek as of today, October 4.  The completion of this purchase agreement and fast track sales in Sweden will increase sales and distribution to meet financial targets. The Forecasted market value of treatment products containing CBD in Sweden is estimated to reach 0.5 billion euros in 2028. This purchase agreement not only increases sales and distribution but also helps CS MEDICA expand its market shares and brand visibility in Sweden.

This press release contains inside information that CS MEDICA A/S is required to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on October 4, 2021 at 13:19 CEST.